GlobeNewswire by notified

Viralgen receives cGMP certification to produce rAAV commercial grade product at new facility in San Sebastian, Spain

Share

-- Certification expands Viralgen's capacity threefold and positions the company as a world-leading CDMO --

-- New facility operates single-use bioreactors from 50 to 2,000 liters and manufactures research, clinical and commercial grade rAAV vectors using Pro10™, the leading cell line on the market --

SAN SEBASTIAN, Spain, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Viralgen Vector Core (Viralgen), an independently operated subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio), and a member of the Bayer worldwide group of companies, has received Certified Good Manufacturing Practices (cGMP) certification for the manufacture of human medicinal products, investigational medicinal products and sterile or biological active substances. This certification was granted following a successful inspection by the Spanish Agency for Medicines and Medical Devices (AEMPS), a part of the European Medicines Agency (EMA) network. The company now operates two facilities in San Sebastian, Spain, with seven state-of-the-art single-use suites that have up to 2,000 liters of manufacturing capacity, making it a world-leading contract development and manufacturing organization (CDMO).  

Viralgen is now licensed for the commercial manufacturing of recombinant adeno-associated virus (rAAV) gene therapies up to 2,000 liters and has completed seven successful runs at this maximum scale. This first phase of the expansion of the new facility, which has added 300,000 square feet of clinical and commercial rAAV manufacturing, is now complete. The new facility currently has three independent state-of-the-art quality control labs and commercial manufacturing suites with 500- and 2,000-liter single-use bioreactors. Viralgen anticipates opening additional manufacturing, science and technology (MSAT) and analytical development space at the same facility at the end of Q1 2023.

"Being a fully integrated CDMO, we offer a continuum of products and services, including process, analytical development, stability studies and fill and finish for all types of rAAV serotypes," said Jimmy Vanhove, CEO of Viralgen. "This can significantly shorten the time to market, help with predictable cost of goods and reduce the waiting time experienced by patients who have run out of options and hope for breakthrough treatments."

With this approval, Viralgen expands its ability to partner with customers in the rAAV space that are initiating Phase III studies and seeking approvals to commercialize their products. This builds on the company's achievement of its 2022 pivotal milestone, which was the manufacturing over 135 batches of clinical and preclinical material, and its enabling more than 24 INDs since its inception in 2019.

"With this certification, we have three times the rAAV production capacity we had previously. This solidifies our position as a global leader in the CDMO rAAV field", said Javier García, co-founder and Chairman of the Board of Viralgen. "We are now able to manufacture at the industry's largest scale and supply Phase III and commercial products for our global customers."

Viralgen was created in 2017 to respond to the unmet need for the manufacturing of gene therapies, with the goal of helping broaden access to these life-saving therapeutics around the world. Viralgen specializes in the production of rAAV vectors and has built an optimized facility that maximizes the throughput and efficiency of the proprietary Pro10™ based suspension manufacturing platform, enabling industry-leading yields, scalability and speed to market. Viralgen is a fully integrated company, which supplies research, cGMP and commercial grade material from 250 to 2,000 liters in scale, including process development, formulation and filling. 

About Viralgen
Viralgen, an independently operated Contract Development and Manufacturing Organization (CDMO), was founded in 2017 as a joint venture between AskBio and Columbus Venture Partners (a venture capital firm based in Spain). As one of the world's leading manufacturers of cGMP-certified AAV, Viralgen uses the Pro10™ based suspension manufacturing platform, a technology licensed from AskBio and developed by co-founder R. Jude Samulski, PhD, at University of North Carolina. It is believed that Pro10™ increases scalability, performance and precision of AAV therapies. Located in Spain, in the Gipuzkoa Science and Technology Park, Viralgen produces AAV gene therapy treatments for pharmaceutical and biotech companies with the aim of accelerating the delivery of new treatments that can improve patients' lives.

The company's clinical facilities have four cGMP manufacturing suites, with 250-liter and 500-liter bioreactors. In 2020, Viralgen expanded within the Scientific Park by constructing a new building for increased manufacturing capacity. The new space includes three additional cGMP suites with a manufacturing capacity of 2,000 liters each. 
Viralgen has more than 420 employees, with three quarters of these holding advanced degrees. This talented workforce supports a range of core capabilities in quality assurance, quality control, analytical development and process development, all of which are critical to shortening the time to market and supporting customers with the regulatory process.

For more information, visit viralgenvc.com.

For more information and interviews, please contact:
Priscilla Assumpção
+34 640 817 276
passumpcao@viralgenvc.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ULTRA Abu Dhabi Drops Stacked Phase One Lineup31.1.2023 23:00:00 CET | Press release

AFROJACK, CALVIN HARRIS, ILLENIUM, NERVO, NGHTMRE, SKRILLEX to headline the Main Stage. ADAM BEYER, AMELIE LENS, SASHA & JOHN DIGWEED to lead Resistance. ULTRA Abu Dhabi to be held at ETIHAD PARK, YAS ISLAND, ABU DHABI on SATURDAY 4 & SUNDAY 5 MARCH 2023. SEOUL, South Korea, Jan. 31, 2023 (GLOBE NEWSWIRE) -- UC Global, the regional partner of ULTRA Worldwide in the United Arab Emirates and the local organizer of ULTRA Abu Dhabi, has announced the first wave of headliners set to play its inaugural edition Saturday 4 and Sunday 5 March 2023. Ever since the announcement that ULTRA Worldwide would be headed to the Middle East for the very first time, anticipation has reached a fever pitch as to which artists would be coming to the region. Now, the wait is finally over as the festival's stellar Phase One lineup has been revealed. Multi-award-winning and platinum-record-selling artist Afrojack is no stranger to the ULTRA main stage and will be on hand to deliver yet another high-octane set.

LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK31.1.2023 22:30:00 CET | Press release

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is the only fingerstick NT-proBNP test currently commercially available.The LumiraDx NT-proBNP test is a rapid microfluidic immunofluorescence assay that can aid in the diagnosis of congestive heart failure (CHF).Available on the same point of care (POC) Platform as LumiraDx’s high sensitivity SARS-CoV-2 antigen, HbA1c, D-Dimer, INR, CRP, Flu A/B, RSV, SARS-CoV-2 antibody, SARS-CoV-2 antigen pool, SARS-CoV-2 Ag Ultra and Ultra Pool tests.*LumiraDx is partnering with Medtronic and a number of local healthcare trusts and charities in the UK to launch the Your Heart Matters Bus initiative where members of the public will be offered free heart health checks, LumiraDx NT-proBNP test results as indicated and medical information through a mobile walk-on service. LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE

International Petroleum Corporation Updated Share Capital31.1.2023 21:30:00 CET | Press release

International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO)reports the following, in accordance with the Swedish Financial Instruments Trading Act: Following the cancellation of738,243 common shares repurchased by IPC under the share repurchase program,the total number of issued and outstanding common shares of the Corporation is 136,089,756 common shares with voting rights as atJanuary 31, 2023, of which IPC holds71,416 common shares in treasury. International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC’s shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm exchange under the symbol "IPCO". For further information, please contact: Rebecca Gordon VP Corporate

Nokia Corporation: Repurchase of own shares on 31.01.202331.1.2023 20:00:00 CET | Press release

Nokia Corporation Stock Exchange Release 31 January 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 31.01.2023 Espoo, Finland – On 31 January 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL261,4854.33CEUX19,9384.34AQEU23,7644.33TQEX12,8134.34Total318,0004.33 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 20